Hepatitis Delta in Focus: Episode 1 of Answering the Questions on Screening, Diagnosis, and Treatment
In this podcast episode, listen to expert perspectives on HDV screening, diagnosis, and treatment.
Decera Clinical Education Infectious Disease Podcast · Maria Buti MD, Richard H Davis PA-C
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, Maria Buti, MD, and Richard H. Davis, PA-C, address key considerations when screening, diagnosing, and treating patients with hepatitis delta virus (HDV), such as:
- Barriers to screening
- HDV screening based on patient risk factors
- Universal screening for all patients with positive hepatitis B surface antigen (HBsAg)
- Reflex testing
- Availability of commercial testing
- Monitoring suggestions in HBsAg positive and HDV antibody positive patients with negative HDV RNA
- Limitations to evaluating advanced fibrosis in patients with HDV
- Data on novel HDV therapies (eg, bulevirtide and lonafarnib)
- Extending HDV therapy (eg, peginterferon) based on treatment response
- Stopping rules (eg, HDV RNA negativity, HBsAg loss) for discontinuing HDV therapy
Faculty:
Maria Buti, MD
Professor of Medicine
Hospital Universitario Vall d’Hebron
Barcelona, Spain
Richard H. Davis, PA-C
Senior PA
Gastroenterology
University of Florida
UF Health
Gainesville, Florida
Link to full program:
http://bit.ly/3yp1Lxf
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.